Today, via the Internet and it’s array of highly accessible, ‘do it yourself’ portals into the thoughts of the socially, intellectually and financially elite, it’s never been easier to get a glimpse into the worldview of the rich and famous. So, what, for example, does Clay Siegall, Doctor, Ph.D. and co-founder of Seattle Genetics have to share to the world via his WordPress page? A quick glance reveals news stories, with scientific and medical bias, proving that topics germane to Siegall’s career continue to consume his off-hours.
There’s a link to North Country Public Radio and a story about brain research into better concentration. A second NPR link asks whether monies required for stem cell studies will be allowed to flow, or be stymied, by state politicians. One can appreciate why a world-renowned geneticist would be interested in such a decision.
A third link goes to an ESPN story, assuring fans of rookie quarterback, Deshaun Watson, that his torn ACL is recovering ahead of its anticipated timeline. As a medical practitioner, Siegall undoubtedly appreciates the trauma and recovery process of a torn anterior cruciate ligament more than most. But it’s also likely he’s a football fan.
The recipient of a B.S. in Zoology, from the University of Maryland and a Ph.D. in Genetics from George Washington University, Siegall has since put the greater part of his work emphasis into cancer research, both in the realm of developing therapies, and in the area of funds accrual, successfully obtaining more than 300 million from investors and philanthropists.
Siegall’s professional resume reads like a who’s who in big-time medical compsnies, encompassing Bristol Myers Squibb Pharmaceuticals, Alder Biopharmaceuticals, Mirna Therapeutics Inc, just to name a few. Today, Siegall is where he’s been since 1998, firmly at the helm of Seattle Genetics, where he reigns as president and CEO. However, Siegall isn’t one to rest on his laurels, which include nine patents and more than fifty scientific texts authored. Under Siegall, his company continues to create a wide-ranging portfolio of new drug and treatment candidates, with a strong focus on antibody technologies.